predominantly in T lymphocytes. Cyclosporin A, possibly in its inhaled form, or Background -The allergen-induced late other agents which prevent cytokine gene asthmatic reaction (LAR) is associated transcription may therefore have potential with mucosal inflammation involving in ameliorating the inflammatory comseveral cell types including activated T ponent of asthma. lymphocytes and eosinophils. In contrast, (Thorax 1997;52:447-452) the early asthmatic reaction (EAR) is considered to result from rapid allergenKeywords: cyclosporin A, eosinophils, late asthmatic induced release of bronchoconstrictor reactions. mediators from IgE sensitised mast cells. Cyclosporin A has efficacy in chronic severe corticosteroid-dependent asthma It is well recognised that bronchial allergen and is believed to act principally by in-challenge of appropriately sensitised atopic hibiting cytokine mRNA transcription in asthmatic subjects provokes an immediate T lymphocytes. However, it has effects on bronchoconstrictor response (usually within 30 other cell types in vitro, including the minutes) which resolves within 1-2 hours. This inhibition of exocytosis/degranulation is known as the early asthmatic reaction (EAR). events in mast cells. It was therefore In some asthmatic subjects this is followed by hypothesised that cyclosporin A would a more sustained delayed-in-time late phase attenuate both the EAR and LAR in sub-asthmatic reaction (LAR) which peaks within jects with mild asthma.
corticosteroids during the 12 months preceding committee of the hospital.
B=short acting agonist; IS=inhaled corticosteroid; NS=intranasal corticosteroid; C=cat dander; HDM=house dust mite; TGP=timothy grass pollen; FEV 1 =forced expiratory volume in one second; PC 20 =concentration of allergen provoking a fall of 20% in FEV 1 .
 
This was a double blind, placebo controlled, crossover study. The study period involved three inhaled allergen challenges with an inLow doses of the immunosuppressive agent cyclosporin A have been found to be effective terval of at least two weeks between each challenge. An initial challenge determined the in the treatment of a number of chronic inflammatory diseases characterised by T allergen concentration sufficient to provoke a 20% reduction in FEV 1 from the prechallenge lymphocyte activation [13] [14] [15] [16] and there is accumulating evidence for a role for activated T value (PC 20 ) within 15 minutes of allergen exposure (the EAR). Patients who developed cells in the pathogenesis of asthma. [17] [18] [19] [20] [21] When cyclosporin A was added to current medication an LAR (defined as a decrease in FEV 1 of >15% from baseline between 4-8 hours after in chronic severe oral glucocorticoid-dependent asthmatic subjects over a three month challenge) were enrolled into the study. Patients received either two single doses of 500 mg period there was an improvement in lung function and fewer disease exacerbations. 22 In a cyclosporin A (in capsular form) or matched placebo before the two subsequent challenges subsequent nine month study low dose oral cyclosporin A, but not placebo, significantly in a predetermined random order. All other medication was withheld for at least eight hours reduced the requirement for oral glucocorticoids and also produced a significant im-before each allergen challenge.
At the initial assessment a full explanation provement in morning peak expiratory flow rates. 23 of the study was given, the patient's history was taken and examination performed. Patients Despite these observations it is not clear precisely how cyclosporin A ameliorates chronic with any known contraindications to receiving cyclosporin A were excluded. Specific exclusion asthma since, in addition to its inhibitory effects on the release of eosinophil-active cytokines from criteria were a previous or current history of gastrointestinal or liver disorders that could activated T lymphocytes, 24 25 it also inhibits other cellular functions including the rapid mediator affect absorption, distribution, metabolism or excretion of the drug, as well as renal imrelease from mast cells in vitro and basophils ex vivo. 26 27 In order to dissect partially the pairment as shown by one of the following: proteinuria (>0.3 g/l by dipstick analysis), possible effects of cyclosporin A on the late phase inflammatory and the early phase mast serum creatinine >120 mmol/l, or concomitant treatment with nephrotoxic drugs. Patients cell-mediated responses in vivo we have performed a randomised, double blind, placebo with evidence of impaired liver function (any increases in serum bilirubin, aspartate aminocontrolled, crossover study of the effects of oral cyclosporin A on the allergen-induced EAR transferase, alkaline phosphatase or -glutamyl transferase more than twice the laboratory and LAR in mild atopic asthmatic subjects. We hypothesised that cyclosporin A would inhibit upper limits of normal) were also excluded, as were patients with a history of hypertension, both the EAR (through mast cell stabilisation) and the LAR (through inhibition of cytokine cardiac disease, or epilepsy.
Skin prick tests to a panel of common aeromRNA transcription by a wide variety of cell types).
allergens (extracts of cat dander, dog fur, house dust mite, and timothy grass pollen) were performed, and blood was taken for an eosinophil count. The allergen used for challenge was Methods  selected on the basis of a history of clinical sensitivity supported by a positive skin prick Twelve patients with atopic asthma were recruited from the allergy clinic of the Royal test result (weal diameter at least 3 mm greater than that produced by control solution). The Brompton Hospital, London (table 1). The patients had a clinical history of intermittent allergens selected for each subject are shown in table 1. chest tightness, wheeze or shortness of breath and documented reversible airflow obstruction Allergen sensitivity was determined by skin prick tests with doubling serial dilutions of (20% change in FEV 1 ) which occurred either spontaneously or with treatment in the pre-allergen, starting with 20 000 biological units (BU)/ml house dust mite (Dermatophagoides ceding year. No subject was receiving long acting inhaled or oral agonists. No subject had pteronyssinus), timothy grass extracts (Phleum pratense), or cat dander (ALK, Horsholm, Denreceived immunotherapy or orally administered group.bmj.com on June 23, 2017 -Published by http://thorax.bmj.com/ Downloaded from mark). After challenge with inhaled saline to was repeated after an interval of at least two weeks, with patients receiving the alternative determine the baseline (pre-allergen) FEV 1 , the dose-finding allergen challenge was performed, treatment to that received on their first treatment visit. starting with a twofold dilution below that which produced a 3 mm diameter skin prick weal (threshold dose for a response). Increasing twofold concentration increments (with at least  
The primary outcome measures were the mag-15 minutes between challenges) were given until a 20% decrease in FEV 1 was achieved. nitudes of the early (EAR) and late (LAR) asthmatic responses, defined as the area under Patients inhaled saline or allergen solution delivered by a Wright nebuliser (calibrated to give curve (AUC) of changes in FEV 1 from the baseline (or prechallenge) value during the an output of 0.13 ml/min) by tidal breathing for two minutes. FEV 1 was recorded before periods 0-1 hours and 4-8 hours after the challenge, respectively. The AUC values were challenge, every five minutes after allergen challenge for the first 30 minutes, and then half calculated by the trapezoid method. Differences between the AUC values after cyclohourly for the next eight hours. At some time during the period 4-8 hours after the challenge sporin A and placebo treatments were compared by paired analyses using a non-parapatients were required to demonstrate a decrease in FEV 1 of at least 15% of the baseline metric method for crossover trials in which three separate Wilcoxon signed rank tests were value.
After a period of at least two weeks the performed to analyse the treatment and period effects as well as the treatment-period interpatient received the first dose of study medication (either 500 mg cyclosporin A or action. 28 This method was also used to compare absolute blood eosinophil counts at each time placebo) at 20.00 hours on the evening before allergen challenge. At 08.00 hours the following point. Correlation coefficients were calculated by Spearman's method with correction for tied day venous blood samples were taken for cyclosporin A concentrations and eosinophil counts values. Data analysis was performed by an independent blinded statistician. before the patient received the second dose of the same study medication. At 10.45 hours, after further blood samples had been taken, a saline challenge was performed to determine Results Every subject complied with the treatment, the baseline FEV 1 (defined as the lowest FEV 1 value achieved within 15 minutes following achieving blood cyclosporin concentrations of more than 100 mg/l 12 hours after the first dose saline challenge). The allergen challenge was performed at 11.00 hours using a pre-of cyclosporin. Peak levels just before allergen challenge were more than 250 mg/l (mean (SE) determined dose of antigen (the PC 20 allergen determined at the first visit). The FEV 1 was 820 (130) mg/l). Nine of the 12 subjects reported some side effects (nausea or parthen recorded every five minutes for 30 minutes, then every 30 minutes for eight hours. aesthesia) after taking cyclosporin A while only one reported side effects after placebo treatBlood samples for further measurements of peripheral blood eosinophils were taken three, ment. All side effects were transient, lasting less than six hours, and were self-limiting. six, and 24 hours after allergen challenge and for measurement of cyclosporin A concentrations at 24 hours. The entire procedure  1 FEV 1 measurements at each time point were found to be distributed normally but the AUC values for changes in FEV 1 from baseline were 
There were no significant period effects or treatment-period interactions for either the eosinophil counts or AUC of changes in FEV 1 .
Discussion
In this placebo controlled, double blind study we have shown that cyclosporin A modulated the late, but not the early, bronchoconstrictor reaction to inhaled allergen challenge of sensitised atopic asthmatic subjects. Furthermore, there was a significant correlation between the magnitude of the reduction of the LAR by cyclosporin A and the blood concentrations of cyclosporin A before the challenge. Cyclosporin A also abolished the increase in circulating eosinophils associated with the LAR 24 hours after allergen challenge but did not have any effect on early changes in blood eosinophil counts. Interestingly, the degree of inhibition of the LAR was similar to that observed with inhaled beclamethasone and sodium cromo- single event was higher than that used for prolonged treatment in our previous studies on chronic asthma but was similar (on a mg/kg basis) to that given during induction of with placebo, cyclosporin A treatment was associated with a median reduction in the mag-immunosuppressive therapy before organ transplantation. The objective was to ensure nitude of the LAR of 65.9% (IQR 24.1 to 79.1%). There was a significant correlation that a satisfactory blood concentration of cyclosporin A was rapidly achieved and then between the percentage reduction in the magnitude of the LAR by cyclosporin A compared maintained during the period of maximal inflammatory activity following allergen chalwith placebo and blood cyclosporin A concentrations measured just prior to the allergen lenge. This objective was accomplished in each patient. challenge (r=0.6, p=0.028).
The EAR is generally believed to result from bronchial smooth muscle contraction, vascular leakage, and mucosal oedema subsequent to   The baseline (prechallenge) absolute eos-the rapid release of pharmacological mediators such as histamine, leukotrienes C 4 , D 4 and inophil counts were not significantly different for either treatment (median values 0.2 (IQR E 4 , and prostaglandin D 2 (PGD 2 ) from IgE sensitised mast cells. 2 3 In contrast, the LAR is 0.2 to 0.45)×10 9 /l for cyclosporin A and 0.25 (IQR 0.15 to 0.40)×10 9 /l for placebo, p= thought to be a reflection of bronchial mucosal inflammation. 1 4 Major cellular changes in the 0.56). By three hours after challenge there were small but significant reductions in blood airways associated with the allergen induced LAR include increased numbers of activated eosinophil counts from baseline values with both treatment arms (median for cyclosporin CD4+ T lymphocytes and eosinophils. 6 The mechanism of eosinophil recruitment is com-A 0.15 (IQR 0.1 to 0.35)×10 9 /l, p=0.016; median for placebo 0.2 (IQR 0.1 to 0.30)×10 9 / plex but appears to involve the elaboration of CC chemokines (RANTES, MCP-3, MCP-4 l, p=0.023) but there were no significant differences between the two treatments (p= and eotaxin) as well as the "eosinophil-active" cytokines interleukin (IL)-3, IL-5, and gran-0.94). Similar reductions were observed at six hours (median eosinophil count for cyclosporin ulocyte/macrophage-colony stimulating factor (GM-CSF). 29 30 These cytokines promote eos-A 0.15 (IQR 0.1 to 0.35)×10 9 /l, p=0.031 for changes from baseline; median for placebo 0.1 inophil differentiation and maturation, enhance eosinophil adhesion and locomotion, and pro-(IQR 0.1 to 0.30)×10 9 /l, p=0.008) and again there was no significant difference between long eosinophil survival. 10 In particular, IL-5 is unique in its ability to differentiate the comtreatments (p=0.52). By 24 hours after allergen challenge, however, the eosinophil counts mitted eosinophil precursor terminally. It also has hormone-like effects since in the guinea were not significantly different from baseline during treatment with cyclosporin A (median pig intravenous injection of IL-5 released mature eosinophils from the bone marrow. There was a significant difference (p= inophils, fibroblasts, endothelial and epithelial cells. 20 21 32-36 There is considerable circum-0.024) between the effects of the two treatments on eosinophil counts at 24 hours after stantial evidence that eosinophil-derived products are directly involved in the pathochallenge (fig 2) . group.bmj.com on June 23, 2017 -Published by http://thorax.bmj.com/ Downloaded from genesis of the LAR -for example, the mag-
The explanation most consistent with all of these observations is that, in this in vivo model, nitude of the allergen-induced LAR correlates closely with the numbers of activated eos-cyclosporin A exerted its anti-asthmatic effects mainly through inhibition of transcription and inophils in bronchoalveolar lavage samples. 6 Our observations of early reductions (within translation of cytokines in T lymphocytes, and possibly other cell types, rather than by sigsix hours of bronchial allergen challenge) of peripheral blood eosinophil counts are in line nificantly inhibiting release of mediators from mast cells. In this sense cyclosporin A can be with previous studies 8 9 37 and may reflect early recruitment of eosinophils to the bronchial considered to have anti-inflammatory as well as immunosuppressant properties. Taken tomucosa 38 39 as a result of the rapid release of mast cell derived cytokines and eosinophil gether with the results of previous studies 22 23 these observations provide further indirect supchemoattractants such as TNF-(which promotes transendothelial migration of eos-port for the involvement of eosinophil-active cytokines, of which allergen-specific T lyminophils), leukotriene B 4 , and platelet activating factor (PAF). 32 The possibility that this phe-phocytes are believed to be important sources, in the pathogenesis of inflammation across the nomenon reflected normal circadian variation was eliminated in a separate experiment (data whole spectrum of asthma severity -from patients with mild asthma (such as those parnot shown) in which no significant variations in circulating eosinophil numbers in these sub-ticipating in the present study) to those with severe corticosteroid-dependent asthma. Aljects were observed after bronchial challenge performed at the same time of day with saline though the use of oral cyclosporin A in mild asthma is unjustified because of its poor risk: alone. The eosinophils recruited to the airways are probably involved in the initiation of the benefit ratio, these observations suggest that safer agents which inhibit cytokine gene tranchanges associated with the LAR. The observation that cyclosporin A did not appear scription might prove to be effective treatments for asthma without the potential side effects to affect this early recruitment of circulating eosinophils may help explain why it did not associated with the use of corticosteroids. An inhaled form of cyclosporin A offering the opcompletely abolish the LAR. The late increase in blood eosinophil counts 24 hours after aller-timal combination of good local bioavailability and fewer systemic effects may be one such gen inhalation mirrors that seen in the bronchi and may reflect increased cytokine driven agent, particularly as the anti-inflammatory effects of cyclosporin A appeared to be dose differentiation of eosinophils in the bone marrow and subsequent release of mature eos-related in this study. Indeed, inhaled cyclosporin A has already been shown to inhibit inophils into the circulation.
Cyclosporin A has several anti-inflammatory the LAR in an animal model. 45 Such novel therapeutic agents may hold exciting prospects effects which might be relevant to the observed attenuation of the allergen-induced LAR. Its for the future management of asthma. actions were originally believed to be confined to CD4+ T lymphocytes where it inhibits The ent study, it had no effect on events believed 
